ClinicalTrials.gg
CompletedNCT07002255Updated Jun 3, 2025

A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rifampicin Capsules (RIF)

A Phase 1 interventional study of Azvudine tablets(FNC) and Rifampicin Capsules (RIF) and Azvudine tablets(FNC) and Rifampicin Capsules (RIF) in Healthy, sponsored by Henan Genuine Biotech Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by Henan Genuine Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Dec 2021, registered May 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Azvudine(FNC),a nucleoside reverse transcriptase inhibitor, make itself a better candidate to be co-formulated in other anti-HIV therapies, thus to improve patient's compliance. FNC is a broad-spectrum RNA virus inhibitor that inhibits the novel coronavirus RNA-dependent RNA polymerase (RdRp).

This is a clinical study to evaluate the Interactions between Azvudine Tablets (FNC) and Rifampicin Capsules (RIF) in healthy subjects. This is a single-center, randomized, open-label, three-cycles, three-treatment crossover clinical trial. Subjects was administered orally for 7 consecutive days each cycle, and the washout period between each cycle was 7 days. Biological sample collection and safety examination were performed.

02

Conditions studied

  • Healthy

Keywords

  • Azvudine
03

In context

Lead sponsor

Henan Genuine Biotech Co., Ltd. is the lead sponsor of 13 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy subjects aged ≥ 18 years old and ≤ 45 years old, regardless of gender;
  2. (BMI) within the range of 19.0-26.0 (including the critical value) (BMI = weight (kg) / height 2 (m2)), the weight of men should be ≥ 50.0kg, and the weight of women should be ≥ 45.0kg;
  3. Those who had no birth plan within 2 weeks before screening and within 6 months after the end of the trial and agree to take effective non-drug measures during the trial;
  4. Understand and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Persons with allergic constitutions, history of drug or food allergies, especially those who were allergic to any ingredient in this product and its ;
  2. Individuals with a history of hypoglycemia;
  3. Individuals deemed ineligible by the clinical research physician due to significant clinical abnormalities in medical history, physical examination, laboratory tests, and other related examinations;
  4. Individuals with a history of smoking addiction within 12 months prior to screening (the number of cigarettes smoked ≥5 per day);
  5. Individuals with a history of alcohol abuse within the past 12 months (consuming ≥14 units of alcohol weekly: 1 unit = 285 mL of beer, or 25 mL of spirits, or 150 mL of wine), or who tested positive for alcohol on breath tests prior to study enrollment (testing value >0mg/100mL);
  6. Individuals with a history of substance abuse within the past 12 months or who tested positive for addictive substances prior to enrollment;
  7. Individuals who underwent surgery within the past 3 months, especially those who had had surgeries that would affect drug absorption, distribution, metabolism, or excretion, or those planning to undergo surgery during the study;
  8. Individuals who had taken any medication that interacts with the trial drug in the 30 days prior to screening, such as: isoniazid, ethionamide, chlorphenozine, miconazole, ketoconazole, etc.;
  9. Individuals with a history of cardiovascular, liver, kidney, pulmonary, gastrointestinal, neurological diseases, especially any surgical conditions or disorders that might affect drug absorption, distribution, metabolism, and excretion, or any surgical conditions or disorders that might pose hazards to participants;
  10. Individuals with febrile illness within the 3 days prior to screening;
  11. Individuals who had participated in any other clinical trials within the past 3 months;
  12. Individuals with any history of prescription drugs, over-the-counter drugs, herbal medicine, or dietary supplements within 14 days prior to screening;
  13. Individuals who had been vaccinated against the novel coronavirus within 14 days before screening or other vaccines within 3 months before screening or planed to be vaccinated during the trial;
  14. Individuals who had consumed excessive tea, coffee, and/or caffeinated, xanthine, or alcoholic beverages (more than 8 cups, 1 cup = 250 mL) daily within the 3 months prior to screening;
  15. Individuals who had lost blood or donated ≥200 mL within the past 8 weeks;
  16. Pregnant or breastfeeding women;
  17. Individuals who could not tolerate venipuncture or had a history of vasovagal syncope;
  18. Individuals deemed unsuitable for this study by the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Group 1 : FNC+RIF;RIF;FNC

    Drug: Azvudine tablets(FNC) and Rifampicin Capsules (RIF)

  • Experimental
    Group 2 : FNC;FNC+RIF;RIF

    Drug: Azvudine tablets(FNC) and Rifampicin Capsules (RIF)

  • Experimental
    Group 3 : RIF;FNC;FNC+RIF

    Drug: Azvudine tablets(FNC) and Rifampicin Capsules (RIF)

Interventions

  • DrugAzvudine tablets(FNC) and Rifampicin Capsules (RIF)

    Drug pages: Azvudine · Rifampin

    This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow: FNC 3mg (1 tablet)+RIF 600 mg (4 capsules) (taken at the same time), 1 time a day, orally, for 7 consecutive days; RIF: 600 mg (4 capsules) each time, 1 time a day, orally, for 7 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days.

  • DrugAzvudine tablets(FNC) and Rifampicin Capsules (RIF)

    Drug pages: Azvudine · Rifampin

    This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 10 days. Subjects were administered the drug as follow: FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC 3mg (1 tablet) +RIF 600 mg (4 capsules) (taken at the same time), 1 time a day, orally, for 7 consecutive days; RIF: 600 mg (4 capsules) each time, 1 time a day, orally, for 7 consecutive days.

  • DrugAzvudine tablets(FNC) and Rifampicin Capsules (RIF)

    Drug pages: Azvudine · Rifampin

    This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 10 days. Subjects were administered the drug as follow: RIF: 600 mg (4 capsules), 1 time a day, orally, for 7 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC 3mg (1 tablet)+RIF 600 mg (4 capsules) (taken at the same time), 1 time a day, orally, for 7 consecutive days.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Plasma Concentration at Steady State (Cmax, ss) of Azvudine and Rifampicin

    Time frame: Blood samples were collected on Day 5, 6, 7, 18, 19, 20, 31, 32 and 33 of the study.

  2. Pharmacokinetics (PK): Time to Maximum Plasma Concentration at Steady State (Tmax, ss) of Azvudine and Rifampicin

    Time frame: Blood samples were collected on Day 5, 6, 7, 18, 19, 20, 31, 32 and 33 of the study.

  3. Pharmacokinetics (PK): Elimination of Terminal Half-Life (t1/2) of Azvudine and Rifampicin

    Time frame: Blood samples were collected on Day 5, 6, 7, 18, 19, 20, 31, 32 and 33 of the study.

Secondary outcomes

  1. Occurrence of Adverse Events

    Clinical presentation characteristics, severity, onset time, duration of adverse events, management measures, outcomes, and the correlation with the investigational drug.

    Time frame: From enrollment to the end of the study on Day 34.

07

Study locations

1 site
  • Heping Hospital Affliliated to Changzhi Medical College
    Shanxi, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Mar 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
Jun 3, 2025
StartActual
Dec 20, 2021
Primary completionActual
Mar 22, 2022
CompletionActual
Oct 7, 2023
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07002255
Lead sponsor
Henan Genuine Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Jun 3, 2025
Start date
Dec 20, 2021
Primary completion
Mar 22, 2022
Completion
Oct 7, 2023
Last update
Jun 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azvudine · Rifampin

Start the discussion